Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Role of Transporters01:27

Nonlinear Pharmacokinetics: Role of Transporters

52
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
52
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

153
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
153
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

153
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
153
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

64
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
64
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

385
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
385
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

709
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
709

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Un chapeau" can fit many different heads - A clinical vignette for CASPR2 autoimmune encephalitis.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Combining Sodium-Glucose Co-Transporter-2 Inhibitor Plus Glucagon-Like Peptide-1 Receptor Agonist for Glucose-Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real-World Clinical Practice (CombiKid Study).

Diabetes, obesity & metabolism·2026
Same author

Middle Fossa Dura Implantation of the Bonebridge in Children With Craniofacial Malformations: A Case Report.

Cureus·2026
Same author

Prevalence of epilepsy in Portugal: An epidemiologic population-based study (EPIPORT).

Epilepsy research·2026
Same author

Association Between the Cancer and Aging Research Group Score and Chemotherapy Toxicity in Older Portuguese Patients: A Retrospective Single-Center Study.

Cureus·2026
Same author

Residual physiological abnormalities after pulmonary endarterectomy and balloon pulmonary angioplasty in CTEPH.

PloS one·2026

Related Experiment Video

Updated: Jul 8, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.2K

Pharmacogenetic Variants Can Influence Optical Medication Use.

Diana Alves1, Filipa Ferreira2, Cristina Pereira2

  • 1Medical Science Department, University of Aveiro, 3810- 193 Aveiro, Portugal.

Endocrine, Metabolic & Immune Disorders Drug Targets
|December 19, 2023
PubMed
Summary

Genetic variants in FMO3 and DPYD genes impact drug response. FMO3 variants offer protection against polyps, while DPYD variants can be lethal in cancer patients undergoing fluoropyrimidine chemotherapy, highlighting pharmacogenetics in personalized medicine.

Keywords:
Dihydropyrimidine dehydrogenase deficiencyMetabolic diseasesPersonalized MedicinePharmacogeneticsSingle Nucleotide PolymorphisTrimethylaminuria

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

727
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

33.8K

Related Experiment Videos

Last Updated: Jul 8, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.2K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

727
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

33.8K

Area of Science:

  • Pharmacogenetics
  • Genomics
  • Metabolic Diseases

Background:

  • Single Nucleotide Polymorphisms (SNPs) serve as drug susceptibility biomarkers in metabolic diseases.
  • Alterations in the flavin-containing monooxygenase 3 (FMO3) gene are linked to Sulindac metabolism and Trimethylaminuria (TMAu).
  • DPYD gene variants are associated with dihydropyrimidine dehydrogenase deficiency (DPD), impairing fluoropyrimidine metabolism and causing toxicity.

Purpose of the Study:

  • To investigate the role of genetic variants in drug metabolism and their impact on disease causality and treatment outcomes.
  • To identify specific gene variants that influence drug efficacy and toxicity.
  • To underscore the importance of genetic profiling in personalized medicine.

Main Methods:

  • Gene sequencing to identify Single Nucleotide Polymorphisms (SNPs) and variants.
  • Analysis of genotype-phenotype correlations for drug response.
  • Review of existing literature on pharmacogenetics and drug metabolism.

Main Results:

  • Homozygous FMO3 polymorphisms (c.472G>A and c.923A>G) showed a protective effect against polyp development in Familial Adenomatous Polyposis (FAP).
  • DPYD gene variants (c.1905+1G>A, c.1679T>G, c.2846A>T, and c.1236G>A/HapB3) were associated with lethal toxicity in cancer patients treated with fluoropyrimidine-based chemotherapy.
  • Genetic variations significantly influence individual responses to specific drugs.

Conclusions:

  • Understanding drug metabolism mechanisms is crucial for predicting therapeutic responses.
  • Pharmacogenetics is an essential tool for personalized medicine, enabling prediction of drug efficacy and toxicity.
  • Molecular studies of drug-metabolizing enzymes improve treatment individualization and patient safety.